TY - JOUR
T1 - Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication
AU - Take, Susumu
AU - Mizuno, Motowo
AU - Ishiki, Kuniharu
AU - Kusumoto, Chiaki
AU - Imada, Takayuki
AU - Hamada, Fumihiro
AU - Yoshida, Tomowo
AU - Yokota, Kenji
AU - Mitsuhashi, Toshiharu
AU - Okada, Hiroyuki
N1 - Funding Information:
S. Take and M. Mizuno contributed principally and equally to the study. The authors thank to Drs. Tsuyoshi Okamoto, Tomomi Hakoda, Masako Kataoka, Yoshimi Itoh, Hideaki Inoue (Nippon Kokan Fukuyama Hospital) and Tetsuya Shiota (Fukuwatari Municipal Hospital) for supporting this work and Dr. William R. Brown (Professor Emeritus, University of Colorado School of Medicine, Denver, Colorado, USA) for assistance in preparation of the manuscript.
Publisher Copyright:
© 2019, The Author(s).
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Background and aims: Eradication of Helicobacter pylori reduces the risk of gastric cancer. In this study, we investigated the risk beyond 10 years after eradication of H. pylori. Methods: We conducted a retrospective cohort study of 2737 patients who had yearly endoscopic follow-up after cure of H. pylori infection. For comparison of gastric cancer risk in the second decade of follow-up with that in the first decade, we calculated standardized incidence ratios (SIRs) by dividing the number of observed cases of gastric cancer in the second decade of follow-up by that of expected cases which was estimated using the incidence rate ratio of age in the first decade. Results: During the follow-up for as long as 21.4 years (mean 7.1 years), gastric cancer developed in 68 patients (0.35% per year). The SIRs for diffuse-type gastric cancer was infinity (0 expected case and 4 observed cases) in patients with mild gastric mucosal atrophy and 10.9 (95% confidence interval 4.53–26.1) with moderate atrophy, whereas no significant increase of SIRs was observed in intestinal-type cancer regardless of the grade of baseline gastric atrophy or in diffuse-type cancer in patients with severe atrophy even though who had the highest risk. Conclusions: The longer the follow-up, the greater the risk of developing diffuse-type gastric cancer becomes in patients with mild-to-moderate gastric atrophy at baseline. Endoscopic surveillance should be continued beyond 10 years after cure of H. pylori irrespective of the severity of gastric atrophy.
AB - Background and aims: Eradication of Helicobacter pylori reduces the risk of gastric cancer. In this study, we investigated the risk beyond 10 years after eradication of H. pylori. Methods: We conducted a retrospective cohort study of 2737 patients who had yearly endoscopic follow-up after cure of H. pylori infection. For comparison of gastric cancer risk in the second decade of follow-up with that in the first decade, we calculated standardized incidence ratios (SIRs) by dividing the number of observed cases of gastric cancer in the second decade of follow-up by that of expected cases which was estimated using the incidence rate ratio of age in the first decade. Results: During the follow-up for as long as 21.4 years (mean 7.1 years), gastric cancer developed in 68 patients (0.35% per year). The SIRs for diffuse-type gastric cancer was infinity (0 expected case and 4 observed cases) in patients with mild gastric mucosal atrophy and 10.9 (95% confidence interval 4.53–26.1) with moderate atrophy, whereas no significant increase of SIRs was observed in intestinal-type cancer regardless of the grade of baseline gastric atrophy or in diffuse-type cancer in patients with severe atrophy even though who had the highest risk. Conclusions: The longer the follow-up, the greater the risk of developing diffuse-type gastric cancer becomes in patients with mild-to-moderate gastric atrophy at baseline. Endoscopic surveillance should be continued beyond 10 years after cure of H. pylori irrespective of the severity of gastric atrophy.
KW - Diffuse-type gastric cancer
KW - Eradication therapy
KW - Gastric atrophy
KW - Helicobacter pylori
UR - http://www.scopus.com/inward/record.url?scp=85074718925&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074718925&partnerID=8YFLogxK
U2 - 10.1007/s00535-019-01639-w
DO - 10.1007/s00535-019-01639-w
M3 - Article
C2 - 31667586
AN - SCOPUS:85074718925
SN - 0944-1174
VL - 55
SP - 281
EP - 288
JO - Journal of Gastroenterology
JF - Journal of Gastroenterology
IS - 3
ER -